Skip to content
10-K

Annual Report

Immunome, Inc. IMNM

0001558370-25-003302

← back to feed
Filed
Mar 19, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 14, 2025 86.95M sh
Shares Diluted FY 2024 · Dec 31, 2023 19.84M sh
Capex FY 2024 · Dec 31, 2023 $831K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$7.57M
Cash And Equivalents FY 2024 · Dec 31, 2023 $98.68M
Current Liabilities FY 2024 · Dec 31, 2023 $21.83M
Total Liabilities FY 2024 · Dec 31, 2023 $28.66M
Current Assets FY 2024 · Dec 31, 2023 $144.7M
Total Assets FY 2024 · Dec 31, 2023 $148.54M
Eps Diluted FY 2024 · Dec 31, 2023 −$5.38
Eps Basic FY 2024 · Dec 31, 2023 −$5.38
Sga Expense FY 2024 · Dec 31, 2023 $19.66M
Rd Expense FY 2024 · Dec 31, 2023 $23.09M
Net Income FY 2024 · Dec 31, 2023 −$106.81M
Operating Income FY 2024 · Dec 31, 2023 −$109.53M
Revenue FY 2024 · Dec 31, 2023 $14.02M
Stockholders Equity FY 2024 · Dec 31, 2022 $16.65M